ArriVent BioPharma, Company Insiders
| AVBP Stock | 27.45 0.86 3.23% |
ArriVent BioPharma,'s insiders are aggressively buying. The analysis of the overall insider sentiment regarding ArriVent BioPharma, Common suggests that virtually all insiders are extremely bullish. ArriVent BioPharma, employs about 40 people. The company is managed by 8 executives with a total tenure of roughly 94 years, averaging almost 11.0 years of service per executive, having 5.0 employees per reported executive.
ArriVent BioPharma,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-01-30 | Orbimed Advisors Llc | Acquired 444444 @ 18 | View |
Monitoring ArriVent BioPharma,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ArriVent |
ArriVent BioPharma, Management Team Effectiveness
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3103) %, meaning that it created substantial loss on money invested by shareholders. ArriVent BioPharma,'s management efficiency ratios could be used to measure how well ArriVent BioPharma, manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.45. In addition to that, Return On Capital Employed is likely to drop to -0.52. As of 11/25/2024, Non Current Liabilities Total is likely to grow to about 213.7 K, while Total Current Liabilities is likely to drop slightly above 8 M.As of 11/25/2024, Common Stock Shares Outstanding is likely to drop to about 26.4 M
ArriVent BioPharma, Workforce Comparison
ArriVent BioPharma, Common is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 148,502. ArriVent BioPharma, adds roughly 40.0 in number of employees claiming only tiny portion of equities under Health Care industry.
ArriVent BioPharma, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ArriVent BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on ArriVent BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ArriVent BioPharma, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hillhouse Investment Management, Ltd. over two months ago Acquisition by Hillhouse Investment Management, Ltd. of 555555 shares of ArriVent BioPharma, at 18.0 subject to Rule 16b-3 | ||
Hillhouse Investment Management Ltd over six months ago Conversion by Hillhouse Investment Management Ltd of 3616041 shares of ArriVent BioPharma, | ||
Gordon Carl L over six months ago Conversion by Gordon Carl L of 821827 shares of ArriVent BioPharma, | ||
Gordon Carl L over six months ago Conversion by Gordon Carl L of 469615 shares of ArriVent BioPharma | ||
Jallal Bahija over six months ago Acquisition by Jallal Bahija of 17884 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Gordon Carl L over six months ago ArriVent BioPharma exotic insider transaction detected |
ArriVent BioPharma, Notable Stakeholders
An ArriVent BioPharma, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ArriVent BioPharma, often face trade-offs trying to please all of them. ArriVent BioPharma,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ArriVent BioPharma,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Zhengbin Yao | Chairman, CoFounder | Profile | |
| Stuart MD | President CoFounder | Profile | |
| Winston MBA | CFO Treasurer | Profile | |
| Robin MA | CoFounder COO | Profile | |
| Meghna Chowdary | Senior Strategy | Profile | |
| James JD | General Secretary | Profile | |
| Dandan Dong | Chief Officer | Profile | |
| Yang Wang | Chief Officer | Profile |
About ArriVent BioPharma, Management Performance
The success or failure of an entity such as ArriVent BioPharma, often depends on how effective the management is. ArriVent BioPharma, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ArriVent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ArriVent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.46) | (0.48) |
ArriVent BioPharma, Workforce Analysis
Traditionally, organizations such as ArriVent BioPharma, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ArriVent BioPharma, within its industry.ArriVent BioPharma, Manpower Efficiency
Return on ArriVent BioPharma, Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 8.7M | |
| Working Capital Per Employee | 3.7M | |
| Working Capital Per Executive | 18.5M |
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.